April 1, 1998Nephrology Dialysis Transplantation
Optimal haemoglobin during treatment with recombinant human erythropoietin
Why the study?
Does targeting higher haemoglobin levels during recombinant human erythropoietin treatment improve survival or cardiovascular function in cardiac patients?
Structured PICO
Does targeting higher haemoglobin levels during recombinant human erythropoietin treatment improve survival or cardiovascular function in cardiac patients?
P
Population
Patients receiving recombinant human erythropoietin (r-HuEPO), particularly cardiac patients
I
Intervention
Recombinant human erythropoietin (r-HuEPO) targeted to different haemoglobin levels
C
Comparator
Haemoglobin levels recommended by the ad hoc committee of the National Kidney Foundation
O
Outcome
Survival, cardiovascular function, physical performance, and medical rehabilitation
The optimal target haemoglobin during r-HuEPO treatment remains controversial, and individualization of targets is recommended, particularly in cardiac patients.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
No evidence supports exceeding recommended haemoglobin targets in cardiac patients; leaves open whether individualized higher targets warrant prospective trials.
Cite This Study
Eberhard Ritz (1998) studied this question.